Biotech

Biotech Jonathan Wosen

STAT Plus: Upstart Element ratchets up race for cheaper DNA sequencing with a $200 genome

Biotech Jason Mast

STAT Plus: Still hoping for looser FDA rules, Regeneron says it will test durable antibody for Covid

Biotech Matthew Herper

STAT Plus: Illumina, the DNA sequencing giant, gives Wall Street bad news

Pharma Kate Sheridan

STAT Plus: People hate drug ads on TV. Here’s the 4 issues they complain about most

Biotech Jonathan Wosen

STAT Plus: FDA’s Califf says congressional report on Aduhelm controversy contained ‘no surprises’

Biotech Adam Feuerstein

STAT Plus: New Biogen CEO: New drug launches, more cost cuts, but no ‘radical left turns’ needed

Biotech Matthew Herper

STAT Plus: Novavax replaces CEO, citing need for ‘fresh perspective’

Biotech Jonathan Wosen and Allison DeAngelis

STAT Plus: A flurry of pharma acquisitions kick off JPM week after a slow year for deals

Biotech Jason Mast

STAT Plus: Regeneron’s Eylea sales dip, as competition looms

Biotech Adam Feuerstein

STAT Plus: Arrowhead RNA treatment improves liver scarring in patients, but so does a placebo, clouding study results

Biotech Matthew Herper

STAT Plus: BioMarin executives express confidence around hemophilia gene therapy

Exclusive Jason Mast

STAT Plus: Day One says drug shrinks tumors in common pediatric brain cancer, setting up potential approval

Biotech Adam Feuerstein and Allison DeAngelis

STAT Plus: Money troubles and M&A: What’s on biotech insiders’ minds ahead of a not-so-celebratory JPM week

Biotech Adam Feuerstein

STAT Plus: FDA approves Alzheimer’s drug shown to moderately slow cognitive decline in early stages of the disease

Biotech Jonathan Wosen

STAT Plus: Fate Therapeutics plans mass layoffs, after early end to cell therapy deal with Janssen

Biotech Allison DeAngelis

STAT Plus: Biogen shakes up R&D chief role, makes Singhal permanent replacement

Biotech Jason Mast

STAT Plus: As FDA considers new Alzheimer’s drug, a case study details safety concerns

Biotech Allison DeAngelis

STAT Plus: Roivant-Pfizer inflammatory bowel drug hits high expectations in mid-stage study

Biotech Jason Mast

STAT Plus: Geron, biotech that once sparked talk of immortality, finally gets a (more modest) success

Biotech Adam Feuerstein

STAT Plus: The biotech scorecard for the first quarter: 19 stock-moving events to watch

The Aduhelm Files Damian Garde and Rachel Cohrs

STAT Plus: In wake of House investigation, 5 burning questions for FDA, Biogen, and Alzheimer’s treatments

The Aduhelm Files Rachel Cohrs, Adam Feuerstein and Damian Garde

STAT Plus: FDA, Biogen, and an Alzheimer’s drug approval: 8 key takeaways from congressional investigation

The Aduhelm Files Rachel Cohrs

STAT Plus: ‘Rife with irregularities’: Congressional investigation reveals FDA’s approval of Aduhelm marked by secret discussions, breaches of protocol

The Aduhelm Files Damian Garde and Adam Feuerstein

STAT Plus: Seeking maximum profits, Biogen set an ‘unjustifiably high price’ for Alzheimer’s treatment, investigation finds

Biotech Jason Mast

STAT Plus: Pfizer says hemophilia B gene therapy significantly reduces bleeds

Biotech Damian Garde

STAT Plus: Get ready for ‘the electric vehicles of biopharma’: Three biotech trends to watch in 2023

Biotech Damian Garde

STAT Plus: Eisai and Biogen’s latest Alzheimer’s drug needs to be cheaper than the last one, analysts say

Biotech Brittany Trang

STAT Plus: Gene therapy trial shows promise for treating ‘bubble boy’ syndrome. Now comes the hard part

Biotech Allison DeAngelis

STAT Plus: Young private equity firm Catalio to absorb hedge fund HealthCor, capping off busy year of investment M&A